Anas Mansour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anas Mansour has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Farid Gadelmawla
Faculty of Medicine, Menoufia University, Menoufia, Egypt
2 shared publications - Abdallah Abbas
Faculty of Medicine Al‐Azhar University Damietta Egypt
1 shared publication Abdullah Farahat Elbanna
Faculty of Medicine, Al-Azhar University , Cairo
1 shared publication- Ahmed Elbataa
Faculty of Medicine, Al-Azhar University , Cairo
1 shared publication Ahmed Elshahat
Faculty of Medicine, Al-Azhar University , Cairo
1 shared publicationAhmed H. Abdelaal
Faculty of Medicine, Minia University, Minia, Egypt
1 shared publication
Latest Publications
- 9 September 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Clinical Outcomes of Conduction System versus Right Ventricular Pacing after TAVR: A Systematic Review and Meta‐Analysis
Background: Permanent pacemaker implantation is required in up to 25% of patients after transcatheter aortic valve replacement (TAVR). Conventional right ventricular pacing (RVP) may promote dyssynchrony, whereas conduction system pacing (CSP) preserves physiological activation. Research Question: Does CSP improve clinical, echocardiographic, electrical, and procedural outcomes compared with RVP in patients requiring pacing after TAVR? Methods: We conducted a PROSPERO‐registered systematic review and meta‐analysis following PRISMA 2020. PubMed, Embase, Scopus, and ClinicalTrials.gov were searched through June 2026 for randomized and comparative observational studies of CSP versus RVP after TAVR. Random‐effects models generated risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs). Prediction intervals, cumulative meta‐analysis, leave‐one‐out analyses, and GRADE assessment were performed. Results: Six studies, one randomized trial and five observational studies, enrolled 675 patients (CSP, n = 344; RVP, n = 331). CSP was associated with fewer heart‐failure hospitalizations (RR 0.49, 95% CI 0.29–0.83; p = 0.017; I 2 = 5%) and shorter paced QRS duration (MD −31.05 ms, 95% CI −34.07 to −28.02; p < 0.001; I 2 = 0%). All‐cause mortality, cardiovascular death, and change in left ventricular ejection fraction did not differ significantly. Implantation success was modestly lower with CSP (RR 0.91; p = 0.014). Conclusion: CSP was associated with fewer heart‐failure hospitalizations and shorter paced QRS duration than RVP after TAVR. Evidence was predominantly observational, and no significant differences were demonstrated in mortality or change in left ventricular ejection fraction. The potential clinical relevance of CSP when a high ventricular pacing burden is anticipated remains plausible but was not directly demonstrated by the available data; adequately powered randomized trials are required before routine adoption.
- 9 September 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Clinical Outcomes of Conduction System versus Right Ventricular Pacing after TAVR: A Systematic Review and Meta‐Analysis
Background: Permanent pacemaker implantation is required in up to 25% of patients after transcatheter aortic valve replacement (TAVR). Conventional right ventricular pacing (RVP) may promote dyssynchrony, whereas conduction system pacing (CSP) preserves physiological activation. Research Question: Does CSP improve clinical, echocardiographic, electrical, and procedural outcomes compared with RVP in patients requiring pacing after TAVR? Methods: We conducted a PROSPERO‐registered systematic review and meta‐analysis following PRISMA 2020. PubMed, Embase, Scopus, and ClinicalTrials.gov were searched through June 2026 for randomized and comparative observational studies of CSP versus RVP after TAVR. Random‐effects models generated risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs). Prediction intervals, cumulative meta‐analysis, leave‐one‐out analyses, and GRADE assessment were performed. Results: Six studies, one randomized trial and five observational studies, enrolled 675 patients (CSP, n = 344; RVP, n = 331). CSP was associated with fewer heart‐failure hospitalizations (RR 0.49, 95% CI 0.29–0.83; p = 0.017; I 2 = 5%) and shorter paced QRS duration (MD −31.05 ms, 95% CI −34.07 to −28.02; p < 0.001; I 2 = 0%). All‐cause mortality, cardiovascular death, and change in left ventricular ejection fraction did not differ significantly. Implantation success was modestly lower with CSP (RR 0.91; p = 0.014). Conclusion: CSP was associated with fewer heart‐failure hospitalizations and shorter paced QRS duration than RVP after TAVR. Evidence was predominantly observational, and no significant differences were demonstrated in mortality or change in left ventricular ejection fraction. The potential clinical relevance of CSP when a high ventricular pacing burden is anticipated remains plausible but was not directly demonstrated by the available data; adequately powered randomized trials are required before routine adoption.
- Open Access
- 11 August 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 49 (11) , 1748-1761
Diagnostic Accuracy of 12‐Lead ECG Algorithms for Accessory Pathway Localization in WPW: A Meta‐Analysis
Background: In Wolff–Parkinson–White (WPW) syndrome, accurate localization of accessory pathways before catheter ablation can improve procedural planning and efficiency. Several 12‐lead electrocardiographic (ECG) algorithms have been proposed, but their diagnostic performance has not been consistently established. We performed a systematic review and meta‐analysis to assess the accuracy of ECG‐based algorithms for accessory pathway localization in manifest WPW. Methods: Following PRISMA‐DTA recommendations, PubMed, EMBASE, Cochrane CENTRAL, Web of Science, and Scopus were searched from January 1990 to January 2026. Studies enrolling adult or pediatric patients with manifest pre‐excitation who underwent electrophysiological study (EPS) and catheter ablation were included. Successful localization during EPS/ablation served as the reference standard. Random‐effects models were used to calculate pooled diagnostic accuracy, sensitivity, specificity, and diagnostic odds ratios (DOR). Summary receiver operating characteristic and leave‐one‐out sensitivity analyses were also performed. Results: Seventeen studies involving 3159 patients met inclusion criteria. The pooled diagnostic accuracy of ECG algorithms was 0.91 (95% CI 0.85–0.94), although heterogeneity was substantial (I 2 = 91.4%). Pooled sensitivity was 0.87 (95% CI 0.73–0.94), and pooled specificity was 0.98 (95% CI 0.95–0.99; I 2 = 0%). The pooled DOR was 297.17 (95% CI 46.33–1906.19; p <0.0001). Sensitivity analyses showed stable results after sequential exclusion of individual studies. Conclusion: Twelve‐lead ECG algorithms provide high diagnostic performance for accessory pathway localization in manifest WPW and may be useful adjuncts for pre‐ablation planning, although invasive electrophysiological mapping remains essential.
- 11 August 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 49 (11) , 1748-1761
Open AccessDiagnostic Accuracy of 12‐Lead ECG Algorithms for Accessory Pathway Localization in WPW: A Meta‐Analysis
Background: In Wolff–Parkinson–White (WPW) syndrome, accurate localization of accessory pathways before catheter ablation can improve procedural planning and efficiency. Several 12‐lead electrocardiographic (ECG) algorithms have been proposed, but their diagnostic performance has not been consistently established. We performed a systematic review and meta‐analysis to assess the accuracy of ECG‐based algorithms for accessory pathway localization in manifest WPW. Methods: Following PRISMA‐DTA recommendations, PubMed, EMBASE, Cochrane CENTRAL, Web of Science, and Scopus were searched from January 1990 to January 2026. Studies enrolling adult or pediatric patients with manifest pre‐excitation who underwent electrophysiological study (EPS) and catheter ablation were included. Successful localization during EPS/ablation served as the reference standard. Random‐effects models were used to calculate pooled diagnostic accuracy, sensitivity, specificity, and diagnostic odds ratios (DOR). Summary receiver operating characteristic and leave‐one‐out sensitivity analyses were also performed. Results: Seventeen studies involving 3159 patients met inclusion criteria. The pooled diagnostic accuracy of ECG algorithms was 0.91 (95% CI 0.85–0.94), although heterogeneity was substantial (I 2 = 91.4%). Pooled sensitivity was 0.87 (95% CI 0.73–0.94), and pooled specificity was 0.98 (95% CI 0.95–0.99; I 2 = 0%). The pooled DOR was 297.17 (95% CI 46.33–1906.19; p <0.0001). Sensitivity analyses showed stable results after sequential exclusion of individual studies. Conclusion: Twelve‐lead ECG algorithms provide high diagnostic performance for accessory pathway localization in manifest WPW and may be useful adjuncts for pre‐ablation planning, although invasive electrophysiological mapping remains essential.
- 26 May 2026
- Published by SAGE Publications in International Journal of Stroke
Safety and efficacy of early antiplatelet therapy after intravenous thrombolysis for acute ischemic stroke: A comprehensive meta-analysis with trial sequential analysis
Background: Early antiplatelet therapy after intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) patients may prevent re-occlusion and early neurological deterioration, but it could increase hemorrhagic transformation. Evidence remains conflicting, particularly with emerging contemporary trials. Methods: We conducted a Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)-guided systematic review of randomized controlled trials (RCTs) comparing early antiplatelet therapy (eAPT) initiated within 24 h after IVT (with or without thrombectomy) versus standard timing (>24 h), placebo, or no antiplatelet therapy (CRD420251276445). Random-effects models were used to estimate odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals (CIs). Trial sequential analysis, subgroup analyses, meta-regression, and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) certainty ratings were performed. Results: Twelve RCTs with 4595 patients were included. Early antiplatelet therapy led to higher non-significant odds of symptomatic intracranial hemorrhage (sICH; OR = 1.68, 95% CI = 0.94–3.01; I 2 = 10.4%; GRADE moderate), and mortality (OR = 1.15, 95% CI = 0.83–1.58; I 2 = 14.8%; GRADE moderate) but not intracranial hemorrhage (OR = 1.01, 95% CI = 0.64–1.60; I 2 = 52.6%; GRADE low). Functional outcomes were not improved: Modified Rankin Scale (mRS) 0–1 (OR = 1.10, 95% CI = 0.83–1.46; I 2 = 60.5%; GRADE low) and mRS 0–2 (OR = 1.27, 95% CI = 0.89–1.80; I 2 = 73.4%; GRADE very low). Trial sequential analysis indicated evidence remains inconclusive. Agent-specific subgroup analyses suggested higher sICH with early aspirin (OR = 2.13, 95% CI = 1.02–4.45) and possible benefit for mRS 0–2 with tirofiban (OR = 2.07, 95% CI = 1.25–3.43). Conclusion: Routine early antiplatelet therapy within 24 h after IVT does not provide conclusive functional benefit, and our analysis cannot exclude clinically meaningful hemorrhagic harm. Further adequately powered RCTs are needed to define whether any selected regimen—especially tirofiban—has a favorable risk–benefit profile.
- 26 May 2026
- Published by SAGE Publications in International Journal of Stroke
Safety and efficacy of early antiplatelet therapy after intravenous thrombolysis for acute ischemic stroke: A comprehensive meta-analysis with trial sequential analysis
Background: Early antiplatelet therapy after intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) patients may prevent re-occlusion and early neurological deterioration, but it could increase hemorrhagic transformation. Evidence remains conflicting, particularly with emerging contemporary trials. Methods: We conducted a Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)-guided systematic review of randomized controlled trials (RCTs) comparing early antiplatelet therapy (eAPT) initiated within 24 h after IVT (with or without thrombectomy) versus standard timing (>24 h), placebo, or no antiplatelet therapy (CRD420251276445). Random-effects models were used to estimate odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals (CIs). Trial sequential analysis, subgroup analyses, meta-regression, and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) certainty ratings were performed. Results: Twelve RCTs with 4595 patients were included. Early antiplatelet therapy led to higher non-significant odds of symptomatic intracranial hemorrhage (sICH; OR = 1.68, 95% CI = 0.94–3.01; I 2 = 10.4%; GRADE moderate), and mortality (OR = 1.15, 95% CI = 0.83–1.58; I 2 = 14.8%; GRADE moderate) but not intracranial hemorrhage (OR = 1.01, 95% CI = 0.64–1.60; I 2 = 52.6%; GRADE low). Functional outcomes were not improved: Modified Rankin Scale (mRS) 0–1 (OR = 1.10, 95% CI = 0.83–1.46; I 2 = 60.5%; GRADE low) and mRS 0–2 (OR = 1.27, 95% CI = 0.89–1.80; I 2 = 73.4%; GRADE very low). Trial sequential analysis indicated evidence remains inconclusive. Agent-specific subgroup analyses suggested higher sICH with early aspirin (OR = 2.13, 95% CI = 1.02–4.45) and possible benefit for mRS 0–2 with tirofiban (OR = 2.07, 95% CI = 1.25–3.43). Conclusion: Routine early antiplatelet therapy within 24 h after IVT does not provide conclusive functional benefit, and our analysis cannot exclude clinically meaningful hemorrhagic harm. Further adequately powered RCTs are needed to define whether any selected regimen—especially tirofiban—has a favorable risk–benefit profile.
- 10 November 2025
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 27 (5) , 574-592
Efficacy and safety of pregabalin and duloxetine in painful diabetic neuropathy: a systematic review and meta-analysis
Background and Objective: Pregabalin (PGB) and duloxetine (DLX) are commonly used first-line medications in the clinical management of painful diabetic neuropathy (PDN), yet high-quality comparative evidence is limited. This meta-analysis evaluates the comparative efficacy and safety of PGB versus DLX, focusing on efficacy outcomes such as pain reduction and mental health, and safety outcomes including adverse events in PDN patients. Method: We searched electronic databases for relevant studies assessing the efficacy and safety of PGB and DLX in PDN. The primary outcomes were the mean change of the Visual Analog Scale (VAS) and the improvement ratio for patients achieving ≥ 50% pain reduction. Secondary outcomes include the Numeric Rating Scale (NRS) for pain, the Short Form 12 Health Survey (SF-12), and related adverse events. A random-effects meta-analysis was performed to evaluate these outcomes. Results: We analyzed 19 studies involving 4483 patients. PGB significantly reduced VAS scores at 24 weeks (MD = -0.38; 95% confidence interval [CI], -0.45 to -0.31; P < .0001) and decreased the mental component of SF-12 compared to DLX (MD = -3.36; 95% CI, -6.64 to -0.07; P = .05) and lower rates of achieving >50% pain reduction (risk ratio = 0.88; 95% CI, 0.79 to 0.98; P = .03). Regarding safety, PGB showed a lower incidence of several adverse events, including anorexia, decreased appetite, diarrhea, nausea, and vomiting. However, no significant differences in VAS scores were observed between PGB and DLX at 1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks, and 12 weeks, with similar results observed in NRS. Conclusion: We found that PGB and DLX showed similar efficacy in relieving PDN. Ultimately, the 2 drugs’ similar effectiveness and different safety profiles highlight the importance of considering patient-specific factors when choosing the appropriate treatment.
- 10 November 2025
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 27 (5) , 574-592
Efficacy and safety of pregabalin and duloxetine in painful diabetic neuropathy: a systematic review and meta-analysis
Background and Objective: Pregabalin (PGB) and duloxetine (DLX) are commonly used first-line medications in the clinical management of painful diabetic neuropathy (PDN), yet high-quality comparative evidence is limited. This meta-analysis evaluates the comparative efficacy and safety of PGB versus DLX, focusing on efficacy outcomes such as pain reduction and mental health, and safety outcomes including adverse events in PDN patients. Method: We searched electronic databases for relevant studies assessing the efficacy and safety of PGB and DLX in PDN. The primary outcomes were the mean change of the Visual Analog Scale (VAS) and the improvement ratio for patients achieving ≥ 50% pain reduction. Secondary outcomes include the Numeric Rating Scale (NRS) for pain, the Short Form 12 Health Survey (SF-12), and related adverse events. A random-effects meta-analysis was performed to evaluate these outcomes. Results: We analyzed 19 studies involving 4483 patients. PGB significantly reduced VAS scores at 24 weeks (MD = -0.38; 95% confidence interval [CI], -0.45 to -0.31; P < .0001) and decreased the mental component of SF-12 compared to DLX (MD = -3.36; 95% CI, -6.64 to -0.07; P = .05) and lower rates of achieving >50% pain reduction (risk ratio = 0.88; 95% CI, 0.79 to 0.98; P = .03). Regarding safety, PGB showed a lower incidence of several adverse events, including anorexia, decreased appetite, diarrhea, nausea, and vomiting. However, no significant differences in VAS scores were observed between PGB and DLX at 1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks, and 12 weeks, with similar results observed in NRS. Conclusion: We found that PGB and DLX showed similar efficacy in relieving PDN. Ultimately, the 2 drugs’ similar effectiveness and different safety profiles highlight the importance of considering patient-specific factors when choosing the appropriate treatment.